Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...

Novo Nordisk's semaglutide ... with a low risk of low blood sugar and beneficial effects on weight and appetite. The new oral formulation has been developed with the help of Emisphere Technologies ...